UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
HAEMATOLOGY

Sanofi

S

Sanofi

HaematologyParis, France
Visit Website

About Sanofi

One of the world's largest pharmaceutical companies by revenue, Sanofi has spent more than a century developing medicines that reach patients in over 100 countries. Headquartered in Paris, the French multinational operates across the full spectrum of drug discovery, development, manufacturing and commercialisation, with a portfolio spanning blockbuster biologics, vaccines and small-molecule therapies.

Immunology & Specialty Care

Sanofi's most prominent growth engine in recent years has been its immunology franchise, built substantially around Dupixent (dupilumab), developed in collaboration with Regeneron Pharmaceuticals. Dupixent has become one of the best-selling medicines in the world, approved across multiple inflammatory conditions including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic oesophagitis. The success of this programme has repositioned Sanofi as a leader in type-2 inflammatory disease, and the company continues to expand the Dupixent indication portfolio through ongoing clinical development.

Vaccines & Rare Diseases

Through its Sanofi Vaccines division, the company is one of the world's largest vaccine producers, with programmes covering influenza, meningococcal disease, polio, pertussis and dengue fever, among others. The Genzyme business unit, acquired in 2011, anchors Sanofi's rare disease presence, particularly in lysosomal storage disorders such as Gaucher disease and Fabry disease, where enzyme replacement therapies have been a long-standing specialism.

Sanofi is listed on Euronext Paris and on the NASDAQ in the United States under the ticker symbol SNY. The company employs tens of thousands of people globally, maintains a significant research and development infrastructure across Europe, North America and Asia, and has consistently invested heavily in external partnerships and acquisitions to broaden its pipeline. Key therapeutic priorities include oncology, neurology, rare blood disorders and mRNA-based vaccine platforms, the latter advanced through its collaboration with Translate Bio.

Further information is available at sanofi.com.

Similar Companies

More in Haematology

R

Roche

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology, haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.

View profile
A

AbbVie

AbbVie built one of the world's best-selling medicines in Humira, the anti-inflammatory biologic that reshaped the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease and held the position of the globe's top-revenue drug for over a decade. Spun out of Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie is listed on the New York Stock Exchange under the ticker ABBV and ranks among the largest pharmaceutical companies by market capitalisation. Immunology & Oncology Leadership Immunology remains the company's core franchise, anchored by Humira and its successors Skyrizi (risankizumab) and Rinvoq (upadacitinib), both of which have grown rapidly across multiple approved indications including plaque psoriasis, Crohn's disease and ulcerative colitis. In oncology, AbbVie markets Imbruvica (ibrutinib), a BTK inhibitor developed in partnership with Janssen, and Venclexta (venetoclax), a BCL-2 inhibitor co-developed with Roche, both indicated for certain blood cancers including chronic lymphocytic leukaemia. Neuroscience & Aesthetics Portfolio AbbVie significantly broadened its therapeutic reach with the 2020 acquisition of Allergan, one of the largest pharmaceutical mergers in history. That transaction brought the company Botox (both therapeutic and cosmetic), the migraine portfolio including Ubrelvy and Qulipta, and a range of medical aesthetics products. The neuroscience division now spans migraine prevention, movement disorders and psychiatry, with further pipeline candidates in Parkinson's disease and mood disorders. The aesthetics business, marketed under the Allergan Aesthetics brand, positions AbbVie as a leader in a segment beyond traditional pharmaceuticals. With operations spanning more than 70 countries and a global workforce numbering in the tens of thousands, AbbVie invests heavily in research and development, maintaining a broad pipeline across immunology, oncology, neuroscience and eye care. The company is a constituent of the S&P 500 and is widely followed for its progressive dividend policy. Further information is available at abbvie.com.

View profile
T

Takeda

Founded in Osaka in 1781, Takeda Pharmaceutical Company is one of the oldest and largest pharmaceutical companies in the world, and the biggest in Asia by revenue. Headquartered in Tokyo and listed on the Tokyo Stock Exchange (ticker: 4502) with American Depositary Receipts traded on the New York Stock Exchange, Takeda operates across more than 80 countries and employs approximately 50,000 people globally. Core Therapy Areas Takeda concentrates its research and commercial efforts on a defined set of therapeutic domains: oncology, rare diseases, neuroscience, gastroenterology, and plasma-derived therapies. The gastroenterology franchise has historically been a pillar of the business, built in part through the long-standing proton pump inhibitor category. The oncology pipeline has grown substantially, particularly in haematology, following the 2019 acquisition of Shire, which also brought a major rare disease and immunology portfolio into the company. The Shire Acquisition and Global Scale The circa $62 billion acquisition of Shire, completed in January 2019, was one of the largest pharmaceutical transactions in history and transformed Takeda into a genuinely global top-ten biopharma. It added significant scale in rare haematology, hereditary angioedema, and attention deficit hyperactivity disorder, alongside a substantial plasma-derived immunology business operating under the Takeda Plasma-Derived Therapies division. The combined entity accelerated Takeda's shift from a Japan-centric business to a fully internationalised operation with major research and manufacturing presence in the United States, Europe, and Asia-Pacific. Takeda's research and development investment consistently ranks among the highest in the sector, with a stated commitment to bringing transformative therapies to patients in areas of high unmet medical need. The company maintains a broad pipeline spanning small molecules and large biologics, with particular depth in haematology and immunology. Further information is available at takeda.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy